JP2003514786A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514786A5 JP2003514786A5 JP2001538315A JP2001538315A JP2003514786A5 JP 2003514786 A5 JP2003514786 A5 JP 2003514786A5 JP 2001538315 A JP2001538315 A JP 2001538315A JP 2001538315 A JP2001538315 A JP 2001538315A JP 2003514786 A5 JP2003514786 A5 JP 2003514786A5
- Authority
- JP
- Japan
- Prior art keywords
- chloro
- enyl
- phenyl
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 26
- 150000003839 salts Chemical class 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 230000003000 nontoxic Effects 0.000 description 10
- 231100000252 nontoxic Toxicity 0.000 description 10
- 229910052736 halogen Inorganic materials 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- -1 hydroxyethoxy Chemical group 0.000 description 6
- 229910052717 sulfur Inorganic materials 0.000 description 6
- 150000002148 esters Chemical class 0.000 description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 3
- NKZTZAQIKKGTDB-UHFFFAOYSA-N 2-[2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]ethoxy]ethanol Chemical compound C1=CC(OCCOCCO)=CC=C1C(C=1C=CC=CC=1)=C(CCCl)C1=CC=CC=C1 NKZTZAQIKKGTDB-UHFFFAOYSA-N 0.000 description 2
- IANRKXFMAWMYFE-UHFFFAOYSA-N 3-[[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]methyl]pentan-3-ol Chemical compound C1=CC(OCC(O)(CC)CC)=CC=C1C(C=1C=CC=CC=1)=C(CCCl)C1=CC=CC=C1 IANRKXFMAWMYFE-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atoms Chemical group C* 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- JQXONNSWMJOKNO-UHFFFAOYSA-N 1-(4-chloro-1,2-diphenylbut-1-enyl)-4-(2-methylsulfanylethoxy)benzene Chemical compound C1=CC(OCCSC)=CC=C1C(C=1C=CC=CC=1)=C(CCCl)C1=CC=CC=C1 JQXONNSWMJOKNO-UHFFFAOYSA-N 0.000 description 1
- UHXWJNBAEKBKEO-UHFFFAOYSA-N 1-chloro-4-[4-chloro-1-[4-(2-chloroethoxy)phenyl]-2-(4-chlorophenyl)but-1-enyl]benzene Chemical compound C1=CC(OCCCl)=CC=C1C(C=1C=CC(Cl)=CC=1)=C(CCCl)C1=CC=C(Cl)C=C1 UHXWJNBAEKBKEO-UHFFFAOYSA-N 0.000 description 1
- VYYWCVMTGYXAQJ-UHFFFAOYSA-N 2-[3-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]ethanol Chemical compound OCCOC1=CC=CC(C(=C(CCCl)C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 VYYWCVMTGYXAQJ-UHFFFAOYSA-N 0.000 description 1
- FPDFGJBIULRCBC-UHFFFAOYSA-N 2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]butan-1-ol Chemical compound C1=CC(OC(CO)CC)=CC=C1C(C=1C=CC=CC=1)=C(CCCl)C1=CC=CC=C1 FPDFGJBIULRCBC-UHFFFAOYSA-N 0.000 description 1
- FEXRUSQUTLWESL-UHFFFAOYSA-N 2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenyl]sulfanyl-N,N-dimethylethanamine Chemical compound C1=CC(SCCN(C)C)=CC=C1C(C=1C=CC=CC=1)=C(CCCl)C1=CC=CC=C1 FEXRUSQUTLWESL-UHFFFAOYSA-N 0.000 description 1
- BHNDRXNBYHXZQX-UHFFFAOYSA-N 2-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenyl]sulfanylethanol Chemical compound C1=CC(SCCO)=CC=C1C(C=1C=CC=CC=1)=C(CCCl)C1=CC=CC=C1 BHNDRXNBYHXZQX-UHFFFAOYSA-N 0.000 description 1
- RAQMMGPTKYEDNQ-UHFFFAOYSA-N 2-[4-[4-chloro-1,2-bis(4-chlorophenyl)but-1-enyl]phenoxy]ethanol Chemical compound C1=CC(OCCO)=CC=C1C(C=1C=CC(Cl)=CC=1)=C(CCCl)C1=CC=C(Cl)C=C1 RAQMMGPTKYEDNQ-UHFFFAOYSA-N 0.000 description 1
- LLGRZSWSJOTDCE-UHFFFAOYSA-N 2-[4-[4-chloro-1-(4-chlorophenyl)-2-phenylbut-1-enyl]phenoxy]ethanol Chemical compound C1=CC(OCCO)=CC=C1C(C=1C=CC(Cl)=CC=1)=C(CCCl)C1=CC=CC=C1 LLGRZSWSJOTDCE-UHFFFAOYSA-N 0.000 description 1
- RVAVCGMKBBTXAT-UHFFFAOYSA-N 2-[4-[4-chloro-1-(4-fluorophenyl)-2-phenylbut-1-enyl]phenoxy]ethanol Chemical compound C1=CC(OCCO)=CC=C1C(C=1C=CC(F)=CC=1)=C(CCCl)C1=CC=CC=C1 RVAVCGMKBBTXAT-UHFFFAOYSA-N 0.000 description 1
- KVMMTWUZMVQIKH-UHFFFAOYSA-N 2-[4-[4-chloro-2-(4-chlorophenyl)-1-(4-methoxyphenyl)but-1-enyl]phenoxy]ethanol Chemical compound C1=CC(OC)=CC=C1C(C=1C=CC(OCCO)=CC=1)=C(CCCl)C1=CC=C(Cl)C=C1 KVMMTWUZMVQIKH-UHFFFAOYSA-N 0.000 description 1
- 125000006012 2-chloroethoxy group Chemical group 0.000 description 1
- GGUFILQMOPZGEV-UHFFFAOYSA-N 3-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]propan-1-ol Chemical compound C1=CC(OCCCO)=CC=C1C(C=1C=CC=CC=1)=C(CCCl)C1=CC=CC=C1 GGUFILQMOPZGEV-UHFFFAOYSA-N 0.000 description 1
- YSRHQKVVQONCBO-UHFFFAOYSA-N 3-[4-(4-chloro-1,2-diphenylbut-1-enyl)phenoxy]propane-1,2-diol Chemical compound C1=CC(OCC(O)CO)=CC=C1C(C=1C=CC=CC=1)=C(CCCl)C1=CC=CC=C1 YSRHQKVVQONCBO-UHFFFAOYSA-N 0.000 description 1
- XJLKGBOMSXXMEK-UHFFFAOYSA-N 3-[4-[4-chloro-1-(4-chlorophenyl)-2-phenylbut-1-enyl]phenoxy]propane-1,2-diol Chemical compound C1=CC(OCC(O)CO)=CC=C1C(C=1C=CC(Cl)=CC=1)=C(CCCl)C1=CC=CC=C1 XJLKGBOMSXXMEK-UHFFFAOYSA-N 0.000 description 1
- XZYDRUBEVFWAQF-UHFFFAOYSA-N 3-[4-chloro-1-[4-(2-hydroxyethoxy)phenyl]-2-phenylbut-1-enyl]phenol Chemical compound C1=CC(OCCO)=CC=C1C(C=1C=C(O)C=CC=1)=C(CCCl)C1=CC=CC=C1 XZYDRUBEVFWAQF-UHFFFAOYSA-N 0.000 description 1
- AQYXOGQKFLYPSY-UHFFFAOYSA-N 3-[4-chloro-1-[4-[2-(2-hydroxyethoxy)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol Chemical compound C1=CC(OCCOCCO)=CC=C1C(C=1C=C(O)C=CC=1)=C(CCCl)C1=CC=CC=C1 AQYXOGQKFLYPSY-UHFFFAOYSA-N 0.000 description 1
- WFTBLFDILSTJOO-UHFFFAOYSA-N 4-[4-chloro-1-[4-(2-hydroxyethoxy)phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C1=CC(OCCO)=CC=C1C(C=1C=CC=CC=1)=C(CCCl)C1=CC=C(O)C=C1 WFTBLFDILSTJOO-UHFFFAOYSA-N 0.000 description 1
- 0 C**CN(C)C Chemical compound C**CN(C)C 0.000 description 1
- INLVUCMFFLLDGD-UHFFFAOYSA-N ClCCOCCOC1=CC=C(C=C1)C(=C(CCCl)C1=CC=CC=C1)C1=CC=C(C=C1)Cl Chemical compound ClCCOCCOC1=CC=C(C=C1)C(=C(CCCl)C1=CC=CC=C1)C1=CC=C(C=C1)Cl INLVUCMFFLLDGD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- 230000001833 anti-estrogenic Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001076 estrogenic Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16582899P | 1999-11-16 | 1999-11-16 | |
| US60/165,828 | 1999-11-16 | ||
| PCT/FI2000/000946 WO2001036360A1 (fr) | 1999-11-16 | 2000-11-01 | Derives de triphenylalcene et leur utilisation comme modulateurs selectifs des recepteurs aux oestrogenes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003514786A JP2003514786A (ja) | 2003-04-22 |
| JP2003514786A5 true JP2003514786A5 (fr) | 2008-05-22 |
| JP4202647B2 JP4202647B2 (ja) | 2008-12-24 |
Family
ID=22600649
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001538315A Expired - Lifetime JP4202647B2 (ja) | 1999-11-16 | 2000-11-01 | トリフェニルアルケン誘導体およびエストロゲン選択的受容体モジュレーターとしてのそれらの用途 |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US6576645B1 (fr) |
| EP (1) | EP1235776B1 (fr) |
| JP (1) | JP4202647B2 (fr) |
| KR (2) | KR100877487B1 (fr) |
| CN (2) | CN100441556C (fr) |
| AT (1) | ATE317378T1 (fr) |
| AU (1) | AU778296B2 (fr) |
| BG (1) | BG65853B1 (fr) |
| BR (1) | BRPI0014901B8 (fr) |
| CA (1) | CA2390116C (fr) |
| CZ (1) | CZ304738B6 (fr) |
| DE (1) | DE60025938T2 (fr) |
| DK (1) | DK1235776T3 (fr) |
| EE (1) | EE05126B1 (fr) |
| ES (1) | ES2253268T3 (fr) |
| HK (1) | HK1051850A1 (fr) |
| HR (1) | HRP20020223C1 (fr) |
| HU (1) | HU228512B1 (fr) |
| IL (2) | IL148198A0 (fr) |
| MX (1) | MXPA02002154A (fr) |
| NO (2) | NO328010B1 (fr) |
| NZ (1) | NZ518542A (fr) |
| PL (1) | PL201512B1 (fr) |
| PT (1) | PT1235776E (fr) |
| RU (1) | RU2247715C2 (fr) |
| SK (1) | SK287752B6 (fr) |
| TW (1) | TW593256B (fr) |
| UA (1) | UA76409C2 (fr) |
| WO (1) | WO2001036360A1 (fr) |
| ZA (1) | ZA200201433B (fr) |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| FI111710B (fi) | 2001-05-04 | 2003-09-15 | Hormos Medical Oy Ltd | Menetelmä terapeuttisesti aktiivisen yhdisteen valmistamiseksi |
| US20040248989A1 (en) | 2003-06-05 | 2004-12-09 | Risto Santti | Method for the treatment or prevention of lower urinary tract symptoms |
| JP5013593B2 (ja) | 2003-07-28 | 2012-08-29 | スミスクライン ビーチャム コーポレーション | 化合物 |
| US7196119B2 (en) | 2003-10-21 | 2007-03-27 | The Regents Of The University Of California | Development of new selective estrogen receptor modulators |
| CA2578852A1 (fr) * | 2004-09-03 | 2006-03-09 | Hormos Medical Corporation | Utilisation d'un modulateur selectif du recepteurs des oestrogenes dans la fabrication d'une preparation pharmaceutique utilisee dans une methode de traitement ou de prevention des insuffisances endrogeniques |
| AU2006339325A1 (en) * | 2005-11-09 | 2007-09-07 | Hormos Medical Ltd. | Formulations of fispemifene |
| US20080255078A1 (en) * | 2005-11-22 | 2008-10-16 | Subba Reddy Katamreddy | Triphenylethylene Compounds Useful as Selective Estrogen Receptor Modulators |
| EP1951217A4 (fr) * | 2005-11-22 | 2009-08-12 | Smithkline Beecham Corp | Composes chimiques |
| JP2009516746A (ja) * | 2005-11-22 | 2009-04-23 | スミスクライン ビーチャム コーポレーション | 化合物 |
| WO2007062151A2 (fr) * | 2005-11-22 | 2007-05-31 | Smithkline Beecham Corporation | Composes chimiques |
| KR101505884B1 (ko) | 2006-05-22 | 2015-03-25 | 호르모스 메디칼 리미티드 | 만성 비세균성 전립선염 치료용 선택적 에스트로겐 수용체 조절제 또는 아로마타아제 저해제 |
| CN101636372B (zh) | 2007-02-14 | 2013-03-27 | 霍尔莫斯医疗有限公司 | 有治疗价值的三苯基丁烯衍生物的制备方法 |
| WO2008099060A2 (fr) | 2007-02-14 | 2008-08-21 | Hormos Medical Ltd | Procédés de préparation de fispémifène à partir d'ospémifène |
| US20080312239A1 (en) * | 2007-06-13 | 2008-12-18 | Quatrx Pharmaceuticals Company | Methods for the treatment of erectile dysfunction using fispemifene |
| CA2702710C (fr) | 2007-10-16 | 2013-05-07 | Repros Therapeutics, Inc. | Traitement d'un syndrome metabolique par trans-clomiphene |
| WO2009120999A2 (fr) * | 2008-03-28 | 2009-10-01 | Olema Pharmaceuticals, Inc. | Utilisation d’un promédicament d’endoxifène dans le traitement du cancer de la poitrine |
| US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| DK2526080T3 (da) | 2010-01-19 | 2014-04-28 | Cambrex Karlskoga Ab | Nye fremgangsmåder til fremstilling af benzophenonderivater |
| EP2571923B1 (fr) * | 2010-05-20 | 2014-12-17 | Basf Se | Dérivés de tris(2-hydroxyphényl)méthane, leur production et leur utilisation |
| DE102010027016A1 (de) | 2010-07-09 | 2012-01-12 | Universitätsklinikum Jena | Steroid-Styrylfarbstoff-Konjugate zur Simulation und direkten lichtoptischen Detektion des Verhaltens von Steroiden im lebenden biologischen Gewebe und in Gegenwart von steroidbindenden Proteinen |
| GB2483736B (en) | 2010-09-16 | 2012-08-29 | Aragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| KR101308258B1 (ko) * | 2010-10-15 | 2013-09-13 | 씨제이제일제당 (주) | 엔독시펜의 신규한 제조 방법 |
| CA2861939A1 (fr) * | 2011-12-30 | 2013-07-04 | Centaurus Biopharma Co., Ltd. | Nouveaux derives d'arylalcene et utilisation de ceux-ci en tant que modulateurs selectifs de recepteur d'oestrogene |
| CN102584687A (zh) * | 2011-12-30 | 2012-07-18 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
| CN102532073A (zh) * | 2011-12-30 | 2012-07-04 | 北京赛林泰医药技术有限公司 | 作为选择性雌激素受体调节剂的乙烯衍生物 |
| ES2681023T3 (es) | 2012-02-29 | 2018-09-11 | Repros Therapeutics Inc. | Terapia de combinación para tratar el déficit de andrógenos |
| SG11201405918XA (en) | 2012-03-20 | 2014-10-30 | Seragon Pharmaceuticals Inc | Estrogen receptor modulators and uses thereof |
| WO2014060639A1 (fr) | 2012-10-19 | 2014-04-24 | Fermion Oy | Procédé pour la préparation d'ospémifène |
| US20150321983A1 (en) | 2012-10-19 | 2015-11-12 | Fermion Oy | A process for the preparation of ospemifene |
| IN2013MU00646A (fr) * | 2013-03-04 | 2015-06-26 | Intas Pharmaceuticals Ltd | |
| US9744177B2 (en) * | 2014-03-10 | 2017-08-29 | Endorecherche, Inc. | Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM |
| CN107074722A (zh) * | 2014-09-16 | 2017-08-18 | 盐野义制药株式会社 | 三苯基丁烯衍生物的制造方法 |
| CA2971216A1 (fr) | 2014-12-23 | 2016-06-30 | The Regents Of The University Of California | Procedes d'immunomodulation de cancer et therapie de maladie infectieuse |
| CN108348605B (zh) | 2015-11-10 | 2023-06-09 | 帕拉卡林治疗公司 | 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌 |
| EP3835285A1 (fr) | 2016-03-15 | 2021-06-16 | Shionogi & Co., Ltd | Procédé de production d'un dérivé de phénoxyéthanol |
| KR101819639B1 (ko) * | 2016-06-27 | 2018-01-17 | 주식회사 케미메디 | 신규한 아릴에텐 유도체 및 이를 유효성분으로 함유하는 약제학적 조성물 |
| EP3459936B1 (fr) * | 2016-06-27 | 2022-04-27 | Daegu-Gyeongbuk Medical Innovation Foundation | Nouveau dérivé d'aryléthane et composition pharmaceutique contenant ce dérivé comme principe actif |
| KR102052133B1 (ko) * | 2017-08-10 | 2019-12-05 | 고려대학교 산학협력단 | 당 부가된 오스페미펜, 이의 제조방법 및 이를 유효성분으로 함유하는 약학적 조성물 |
| WO2019103989A1 (fr) * | 2017-11-22 | 2019-05-31 | Temple University-Of The Commonwealth System Of Higher Education | Nouveaux éthers de n,n-dialkylamino-phényle fonctionnalisés et leur méthode d'utilisation |
| US10696659B2 (en) * | 2018-11-21 | 2020-06-30 | Accutar Biotechnology Inc. | Compounds having estrogen receptor alpha degradation activity and uses thereof |
| CA3161892A1 (fr) | 2019-12-23 | 2021-07-01 | Jie Fan | Associations d'agents de degradation du recepteur d'?strogenes et d'inhibiteurs de kinase dependante de cyclines pour le traitement du cancer |
| US11413270B2 (en) | 2020-06-22 | 2022-08-16 | Novmetapharma Co., Ltd. | Method for the treatment of pancreatitis |
| US11850246B2 (en) | 2020-08-04 | 2023-12-26 | Novmetapharma Co., Ltd. | Method for treatment of cytokine release syndrome |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE637389A (fr) | 1962-09-13 | |||
| GB2042519B (en) * | 1979-01-17 | 1983-03-23 | Biorex Laboratories Ltd | 1,1,2-triphenylethane and -ehylene derivatives |
| US4656187A (en) | 1981-08-03 | 1987-04-07 | Eli Lilly And Company | Treatment of mammary cancer |
| GB2126576B (en) * | 1982-06-25 | 1985-06-19 | Farmos Group Limited | Alkane and alkene derivatives |
| FI67538C (fi) * | 1982-05-27 | 1985-04-10 | Farmos Oy | Foerfarande foer framstaellning av (z)-1,2-difenyl-1-(4-(2-(n n-dimetylamino)etoxi)fenyl)-1-buten |
| FI77839C (fi) * | 1982-05-27 | 1989-05-10 | Farmos Oy | Foerfarande foer framstaellning av nya terapeutiskt effektiva trifenylalkan- och alkenderivat. |
| US5491173A (en) | 1982-06-25 | 1996-02-13 | Orion-Yhtyma Oy | Tri-phenyl alkene derivatives and their preparation and use |
| US4729999A (en) | 1984-10-12 | 1988-03-08 | Bcm Technologies | Antiestrogen therapy for symptoms of estrogen deficiency |
| EP0260066B1 (fr) * | 1986-09-11 | 1990-05-09 | National Research Development Corporation | Dérivés du tamoxifène |
| US5189212A (en) | 1990-09-07 | 1993-02-23 | University Of Georgia Research Foundation, Inc. | Triarylethylene carboxylic acids with estrogenic activity |
| US5219548A (en) | 1990-10-01 | 1993-06-15 | Board Of Regents, The University Of Texas System | High affinity halogenated-tamoxifen derivatives and uses thereof |
| CA2092996A1 (fr) | 1990-10-01 | 1992-04-02 | David Yang | Derives de tamoxifene a haute affinite et utilisation |
| US6096874A (en) | 1990-10-01 | 2000-08-01 | Board Of Regents, The University Of Texas System | High affinity tamoxifen derivatives |
| US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
| US5196435A (en) | 1991-11-21 | 1993-03-23 | Eli Lilly And Company | Melatonin derivatives and combinations with antiestrogen compounds for treating mammalian breast carcinoma |
| GB9207437D0 (en) | 1992-04-03 | 1992-05-20 | Orion Yhtymae Oy | Topical administration of toremifene and its metabolites |
| US5446203A (en) | 1992-08-25 | 1995-08-29 | New York University | Synthesis of haloenones and aryl or alkyl substituted enones or alkenes |
| DE4335876A1 (de) | 1993-10-17 | 1995-04-20 | Schering Ag | Kombination von Progesteronantagonisten und Antiöstrogenen mit partialer agonistischer Wirkung für die Hormonsubstitutions-Therapie für peri- und postmenopausale Frauen |
| US5650425A (en) | 1994-04-04 | 1997-07-22 | Pharmos Corporation | Permanently ionic derivatives of steroid hormones and their antagonists |
| US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
| US5604248A (en) | 1994-05-05 | 1997-02-18 | Eli Lilly And Company | Method for minimizing the uterotrophic effect of tamoxifen and tamoxifen analogs |
| US5470883A (en) | 1994-05-23 | 1995-11-28 | Stromberg; Brent V. | Method of treating peripheral vasoconstriction with tamoxifen citrate |
| US5441986A (en) | 1994-07-19 | 1995-08-15 | Pfizer Inc. | Estrogen agonists as remedies for prostate and cardiovascular diseases |
| GB9418067D0 (en) * | 1994-09-07 | 1994-10-26 | Orion Yhtymae Oy | Triphenylethylenes for the prevention and treatment of osteoporosis |
| US5658931A (en) | 1994-09-20 | 1997-08-19 | Eli Lilly And Company | Method for inhibiting mammalian breast carcinoma with tamoxifen, and analogs thereof, and certain naphthyl compounds |
| EP0794771A1 (fr) | 1994-11-29 | 1997-09-17 | Hoechst Marion Roussel, Inc. | Mode d'emploi de derives du triaryl-ethylene pour le traitement et la prevention de l'osteoporose |
| US5821254A (en) | 1995-02-17 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer |
| GB9509572D0 (en) * | 1995-05-11 | 1995-07-05 | Cancer Res Campaign Tech | Cancer therapy |
| DE19526146A1 (de) | 1995-07-07 | 1997-01-09 | Schering Ag | Triphenylethylene, Verfahren zu deren Herstellung, diese Triphenylethylene enthaltene pharmazeutische Präparate sowie deren Verwendung zur Herstellung von Arzneimitteln |
| GB9604577D0 (en) | 1996-03-04 | 1996-05-01 | Orion Yhtymae Oy | Serum cholesterol lowering agent |
| GB9803521D0 (en) * | 1998-02-19 | 1998-04-15 | Orion Yhtymo Oy | New compounds and pharmaceutical compositions thereof |
| US6465445B1 (en) * | 1998-06-11 | 2002-10-15 | Endorecherche, Inc. | Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors |
| TW593256B (en) * | 1999-11-16 | 2004-06-21 | Hormos Medical Oy Ltd | Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
-
2000
- 2000-10-20 TW TW089122073A patent/TW593256B/zh not_active IP Right Cessation
- 2000-11-01 AU AU11503/01A patent/AU778296B2/en not_active Ceased
- 2000-11-01 HU HU0204029A patent/HU228512B1/hu not_active IP Right Cessation
- 2000-11-01 UA UA2002065002A patent/UA76409C2/uk unknown
- 2000-11-01 EP EP00972945A patent/EP1235776B1/fr not_active Expired - Lifetime
- 2000-11-01 CN CNB200610084709XA patent/CN100441556C/zh not_active Expired - Lifetime
- 2000-11-01 EE EEP200200190A patent/EE05126B1/xx unknown
- 2000-11-01 JP JP2001538315A patent/JP4202647B2/ja not_active Expired - Lifetime
- 2000-11-01 CZ CZ2002-1623A patent/CZ304738B6/cs not_active IP Right Cessation
- 2000-11-01 BR BRPI0014901A patent/BRPI0014901B8/pt not_active IP Right Cessation
- 2000-11-01 CA CA002390116A patent/CA2390116C/fr not_active Expired - Lifetime
- 2000-11-01 KR KR1020027006302A patent/KR100877487B1/ko active IP Right Grant
- 2000-11-01 DK DK00972945T patent/DK1235776T3/da active
- 2000-11-01 MX MXPA02002154A patent/MXPA02002154A/es active IP Right Grant
- 2000-11-01 AT AT00972945T patent/ATE317378T1/de active
- 2000-11-01 NZ NZ518542A patent/NZ518542A/xx not_active IP Right Cessation
- 2000-11-01 ES ES00972945T patent/ES2253268T3/es not_active Expired - Lifetime
- 2000-11-01 RU RU2002115871/04A patent/RU2247715C2/ru active
- 2000-11-01 CN CNB008156255A patent/CN1263720C/zh not_active Expired - Lifetime
- 2000-11-01 PT PT00972945T patent/PT1235776E/pt unknown
- 2000-11-01 WO PCT/FI2000/000946 patent/WO2001036360A1/fr active IP Right Grant
- 2000-11-01 SK SK671-2002A patent/SK287752B6/sk not_active IP Right Cessation
- 2000-11-01 KR KR1020087000375A patent/KR20080015924A/ko not_active Application Discontinuation
- 2000-11-01 IL IL14819800A patent/IL148198A0/xx unknown
- 2000-11-01 PL PL355708A patent/PL201512B1/pl unknown
- 2000-11-01 DE DE60025938T patent/DE60025938T2/de not_active Expired - Lifetime
- 2000-11-15 US US09/712,252 patent/US6576645B1/en not_active Expired - Lifetime
-
2002
- 2002-02-14 BG BG106413A patent/BG65853B1/bg unknown
- 2002-02-17 IL IL148198A patent/IL148198A/en not_active IP Right Cessation
- 2002-02-20 ZA ZA200201433A patent/ZA200201433B/en unknown
- 2002-03-14 HR HR20020223 patent/HRP20020223C1/xx not_active IP Right Cessation
- 2002-05-15 NO NO20022317A patent/NO328010B1/no not_active IP Right Cessation
-
2003
- 2003-04-08 US US10/408,303 patent/US6875775B2/en not_active Expired - Lifetime
- 2003-06-10 HK HK03104083A patent/HK1051850A1/xx not_active IP Right Cessation
-
2009
- 2009-10-20 NO NO20093175A patent/NO332328B1/no not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003514786A5 (fr) | ||
| RU2002115871A (ru) | Трифенилалкеновые производные и их применение в качестве селективных модуляторов рецепторов эстрогена | |
| JP2004529174A5 (fr) | ||
| RU2397171C2 (ru) | 9-замещенное производное 8-оксоаденина и лекарственное средство | |
| RU2201924C2 (ru) | Морфолиновое производное и фармацевтическая композиция на его основе | |
| KR950017940A (ko) | β₃작용약으로서 유용한 카테콜아민 대용약 | |
| RU2368604C2 (ru) | Ингибиторы фосфодиэстеразы 4, включающие n-замещенные аналоги анилина и дифениламина | |
| RU2447071C2 (ru) | Производные пиридин-4-ила в качестве иммуномодулирующих агентов | |
| JP2007502806A5 (fr) | ||
| JP2004532209A5 (fr) | ||
| JP2004511462A5 (fr) | ||
| JP2004534035A5 (fr) | ||
| KR850000430A (ko) | 1,2,4-트리아졸-3-온 항우울증제의 제조방법 | |
| RU2006144811A (ru) | Новые цис-имидазолины | |
| JP2005508293A5 (fr) | ||
| JP2009520769A5 (fr) | ||
| JP2004507501A5 (fr) | ||
| JP2004520377A5 (fr) | ||
| JP2003516979A5 (fr) | ||
| RU2004104625A (ru) | Аналоги простагландинов в качестве агонистов рецептора ep4 | |
| JP2009541270A5 (fr) | ||
| RU2008129629A (ru) | Замещенные производные оксадиазола и их применение в качестве лигандов опиоидных рецепторов | |
| RU97113374A (ru) | Производные 4-гидроксипиперидина | |
| KR850006402A (ko) | 항정신병의 1-플루오로페닐부틸-4-(2-피리미디닐) 피페라진 유도체 | |
| JP2002505286A5 (fr) |